Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

Abstract

Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-type experience) and Dread of Ego Dissolution (DED) (similar to anxiety) would predict long-term positive outcomes, whereas sensory perceptual effects would have negligible predictive value.Materials and Methods: Twenty patients with treatment resistant depression underwent treatment with psilocybin (two separate sessions: 10 and 25 mg psilocybin). The Altered States of Consciousness (ASC) questionnaire was used to assess the quality of experiences in the 25 mg psilocybin session. From the ASC, the dimensions OBN and DED were used to measure the mystical-type and challenging experiences, respectively. The Self-Reported Quick Inventory of Depressive Symptoms (QIDS-SR) at 5 weeks served as the endpoint clinical outcome measure, as in later time points some of the subjects had gone on to receive new treatments, thus confounding inferences. In a repeated measure ANOVA, Time was the within-subject factor (independent variable), with QIDS-SR as the within-subject dependent variable in baseline, 1-day, 1-week, 5-weeks. OBN and DED were independent variables. OBN-by-Time and DED-by-Time interactions were the primary outcomes of interest.Results: For the interaction of OBN and DED with Time (QIDS-SR as dependent variable), the main effect and the effects at each time point compared to baseline were all significant (p = 0.002 and p = 0.003, respectively, for main effects), confirming our main hypothesis. Furthermore, Pearson's correlation of OBN with QIDS-SR (5 weeks) was specific compared to perceptual dimensions of the ASC (p < 0.05).Discussion: This report further bolsters the view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health. Future therapeutic work with psychedelics should recognize the essential importance of quality of experience in determining treatment efficacy and consider ways of enhancing mystical-type experiences and reducing anxiety.Trial Registration: ISRCTN, number ISRCTN14426797, http://www.isrctn.com/ISRCTN14426797

Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex

“…Interestingly, the mPFC/ACC is strongly implicated in self-referential processing as well as mentalizing about others (D'Argembeau et al, 2007;Dixon, Thiruchselvam, Todd, & Christoff, 2017). This association between hierarchical position and ego-dissolution is particularly noteworthy given past findings that ego-dissolution and related mystical-type phenomena are key mediators of positive outcomes in psychedelic treatment paradigms (Belser et al, 2017;Johnson et al, 2019;Roseman, Nutt, & Carhart-Harris, 2018;Watts, Day, Krzanowski, Nutt, & Carhart-Harris, 2017).…”

DMT Models the Near-Death Experience

“…Recent work has consistently shown that the occurrence of mystical-type experiences is predictive of long-term therapeutic benefit from psychedelics (Maclean et al, 2011; Garcia-Romeu et al, 2014; Griffiths et al, 2016; Carhart-Harris et al, 2017, 2018; Roseman et al, 2018) and similar mechanisms may be at play in relation to improved mental well-being post NDE (Moody, 1975; Noyes, 1980; Ring, 1980; Groth-Marnat and Summers, 1998). It is pertinent to ask therefore, what common features shared between these states may be responsible for mediating the apparent long-term psychological benefits that follow them.…”

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

“…Recent clinical trials have demonstrated potent and enduring antidepressive and anxiolytic effects of classical psychedelic drugs psilocybin and LSD Carhart-Harris et al 2016;Horstmann et al 2010;Ross et al 2016;Griffiths et al 2016;Grob et al 2011). Several studies have highlighted the mystical nature of the subjective experience resulting from administration of high dose psilocybin or LSD as a mediator for the psychiatric therapeutic benefits (Russ et al 2019;Garcia-Romeu et al 2014;Roseman et al 2018;Haijen et al 2018). However, recent evidence of sustained antidepressant-like effects of psilocybin in an animal rodent model for the study of depression after only a single dose suggests that solely biological mechanisms dependent on 5-HT 2A receptor activation may effectively underlie key CNS effects observed for this class of drug (Hibicke et al 2019).…”